Home/TG Therapeutics/Jenna M. Goldberg
JM

Jenna M. Goldberg

General Counsel and Corporate Secretary

TG Therapeutics

TG Therapeutics Pipeline

DrugIndicationPhase
BRIUMVI (ublituximab)Relapsing Forms of Multiple SclerosisApproved
UblituximabNewly Diagnosed Multiple SclerosisPhase 3
TG-1701B-Cell MalignanciesPhase 1
TG-1801B-Cell MalignanciesPhase 1